Researchers at Beijing Institute of Pharmacology and Toxicology have reported the discovery of novel CRBN-recruiting epidermal growth factor receptor (EGFR) degraders as candidates for the treatment of non-small cell lung cancer (NSCLC). Synthesis and optimization of a series of CRBN-recruiting EGFR degraders led to the identification of compounds [I] and [II] as the lead candidates.